Neuromodulation Devices 2016-2026

LONDON, March 22, 2016 /PRNewswire/ --

Revenue Forecasts for Deep Brain Stimulation, Spinal Cord, Vagus Nerve, Sacral Nerve and Gastric Electrical Applications

Neuromodulation devices - your 2016 guide to trends, opportunities and future revenues
Discover the future of medical devices to stimulate and treat the central nervous system. Neuromodulation devices hold high, rising sales potential. Now you can explore forecasts and see predicted revenues. Assess the expected gains.

Visiongain's updated report predicts those revenues to 2026 at overall world market, submarket and national level. With our new survey you stay ahead in that CNS data and analysis, discovering medical, technological and commercial opportunities and prospects.

With that study you explore what the future holds for those companies. Read on now to investigate neuronal devices, also seeing a revenue prediction below.

Forecasts and other analyses to help your research, knowledge and influence
Do you struggle to find business data on neuromodulation and neurostimulation therapies? Instead today discover potentials of those treatments for brain and other nervous system disorders. Our report analyses the future of that healthcare industry, showing potential gains.

With that updated study make your research, analyses and plans easier and quicker. That way you can also benefit your reputation for commercial insight. See what is possible.

In addition to multilevel forecasting to 2026, our new study shows you results, growth rates, market shares, opinions and discussions. In that report you gain 65 charts, 30 tables and interviews with two organisations. Our work's purpose is to help you stay ahead.

There discover how competition and technological advances shape that industry. Also benefit your knowledge and authority. See what sales are possible from 2016 in the neuromodulators industry and investigate how you can gain. Sections below explain.

Forecasting of that world market and its segments - what is possible?
Our study predicts overall world revenue to 2026 for neuromodulating and neurostimulating technologies.

There, in our work, you also find individual revenue predictions to 2026 for six submarkets at world level:

• Spinal cord stimulation (SCS)
• Deep brain stimulation (DBS)
• Vagus/vagal nerve stimulation (VNS)
• Sacral nerve stimulation (SNS)
• Gastric electrical stimulation (GES)
• Other techniques (grouped forecast), including trigeminal nerve stimulation, cochlear implants, transcranial magnetic stimulation, transcranial direct current stimulation and ultrasonic neuromodulation.

With that analysis you investigate the most promising and lucrative parts of the neuromodulators industry. See how it can progress. Our study predicts high, rising sales. You explore where, when, how and why market expansion can occur.

Our investigation also splits its overall world market into geographical revenue predictions.

National markets - what outlooks for neuromodulators' sales?
Our analyses also show you individual revenue forecasts to 2026 for 11 countries:

• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).

Healthcare developments worldwide stimulate that industry's revenues. With our data you find countries with highest revenues, demand and potential sales. See needs and opportunities. And explore the expected trends, progress and gains.

So how do changes, challenges and technological advances affect that industry and market?

Forces, events and issues influencing that medical devices field
Our updated report explains policies, trends and R&D shaping that industry and market, including these developments:

• Widening applications in treating pain, depression, epilepsy, incontinence, hearing disorders, heart conditions and neurodegenerative diseases, inc. Parkinson's
• Market trends - ageing populations raising demand, personalised healthcare, regulations and changes in that medical devices segment
• Emerging technology - cochlear implants, transmagnetic stimulation (TMS), transcranial direct current stimulation (tDCS) and ultrasonic applications.

With that work you assess the industry's strengths, weaknesses, opportunities and threats, also exploring social, technological, economic and political questions. Those analyses help you assess what stimulates and restrains companies. Explore what the future holds.

Neuromodulation technology - leading companies and 2020 market value
What happens next? From 2016 neuromedical devices hold great potential for investments, medical advances and sales. Our report predicts the world market for those products will reach $9.3bn in 2020, with fast 2016-2026 sales growth. High potentials exist for companies.

• In particular our study discusses performances, activities and potentials of four leading organisations:
  • Medtronic
• Boston Scientific
• St. Jude Medical
• Cyberonics.

Discussions of rising companies appear too. The survey also shows visiongain's interviews with the International Neuromodulation Society and NeuroSigma.

With our analysis you see how that market can develop and perform from 2016, benefiting your insight and authority. See there how you can benefit your research and analysis.

7 ways Neuromodulation Devices 2016-2026 helps you stay ahead of competitors
Our new study benefits your decisions, plans and proposals in these seven main ways:

• Revenue to 2026 for the worldwide neuromodulation devices industry - discover its overall potential
• Predictions to 2026 for 6 submarkets - investigate product categories at world level, finding the most lucrative and promising opportunities
• Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia - discover the best regions and countries for revenue expansion
• Activities of established and rising companies - hear about firms' products, capabilities, advances and outlooks, seeing what is possible
• Technological developments - investigate R&D progress, exploring technological, clinical and commercial opportunities, seeing what is happening and possible
• Interviews with other authorities - discover what organisations there say and do, helping you stay ahead in knowledge
• Analysis of what stimulates and restrains that market - assess challenges and strengths, helping you compete and succeed.

In our investigation you find independent business analysis by visiongain's UK-based team. Gain data found only there, information to help your research, analysis and presentations.

That way you can benefit your authority and reputation for insight. Stay ahead in knowledge.

Trying our analysis now lets you discover sales trends, opportunities and predictions
Our independent study shows you data, trends, opportunities and forecasts for neuromodulation therapy. Please avoid missing out. Instead get our new report here now.

Companies Listed 

Accellent
Accuitive Medical Ventures (AMV)
Advanced Bionics
Advanced Neuromodulation Systems
Avery Biomedical
Axonics Modulation Technologies
Bard Electrophysiology
Bayer AG
Boston Scientific
Boston Scientific Innovation Centre (Shanghai, China)
Boston Scientific Institute for Advancing Science (Shanghai, China)
CardioMems
Cerbomed GmbH
CerebralRx
China Food and Drug Administration
Cirtec
Cochlear
Covidien
Cyberonics
Deep Brain Innovations
Department of Justice (US)
electroCore
European Commission
Foundation Medical Partners
Functional Neuromodulation
Genesys Capital
GlaxoSmithKline (GSK)
Halo Neuroscience
ImThera Medical
International Neuromodulation Society
IoGyn
Johnson & Johnson
Magstim
Mainstay Medical
Med-El
Medtronic
MetaCure
Mindray
Ministry of Health, Labour and Welfare (Japan)
Nanostim
National Health Service (UK)
National Institute for Health and Care Excellence (NICE, UK)
NDI Medical
NEA
NeuroSigma
NeuroStar
Neurotherapies Reset
NeuroTherm
Nevro Corp.
NOVO A/S
Pfizer
Pharmaceuticals and Medical Devices Agency (PMDA)
Roche
Sapiens Steering Brain Stimulation (Purchased by Medtronic)
SceneRay
SetPoint Medical
St. Jude Medical
StarMedTec
Stryker Corporation
Synova
Tyler Laboratory of Neuroscience and Neurotechnology
University of California, San Francisco
Uroplasty
US Food and Drug Administration (FDA)
Wiringless Implantable Stretchable Electronics (WISE)

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100

SOURCE Visiongain